Access to hospital data helped the Croatian healthtech company reduce the clinical work behind its service. AI4Health.Cro’s Ready for Investment Program then supported the development of its business model, leading to financing from Feelsgood Capital.
Personalised healthcare carries an operational challenge that becomes more visible as a company grows. Each new user brings another medical history to examine, another set of test results to interpret and another programme to prepare. Clinical oversight gives the service its credibility, while the time required from doctors places a natural limit on scale.
Agesync, a Croatian company founded by Marko Lončarević, is developing a platform built around personalised programmes for longevity and healthy ageing. The service uses blood-test results and information supplied by users to develop individual recommendations with medical oversight.
Depending on the person’s needs, the programme may cover exercise, nutrition, supplementation, meditation and sleep. It may also include hormone therapy. The underlying proposition is that people seeking to improve their long-term health need guidance shaped around their own data rather than a general set of lifestyle recommendations.
For Agesync, developing the service required progress on two closely connected fronts. The company needed a more efficient way to process health data while preserving doctors’ involvement. It also needed a business model capable of showing investors how personalised care could grow without creating an equivalent increase in clinical workload.
AI4Health.Cro supported both parts of that development. The company gained access to anonymised hospital data that helped improve its technical and operational model. It later participated in the hub’s Ready for Investment Program, where it further developed its business model and prepared for investor engagement. Agesync subsequently secured financing from Feelsgood Capital, an AI4Health.Cro partner.
Using hospital data to improve clinical capacity
Through AI4Health.Cro, Agesync received access to a large, anonymised dataset of blood-test results from two Croatian hospitals.
The data helped the company develop the process through which its algorithm reads and organises test results before they are reviewed by a doctor. This reduced the amount of repetitive work required during onboarding and allowed clinicians to focus on interpretation and personalised recommendations.
According to Lončarević, the revised workflow enabled one doctor to support approximately ten users in the time previously required to handle one.
That improvement was central to Agesync’s development. Personalised services depend on professional oversight, and clinical time remains a limited resource. By preparing health information for medical review, the platform increased capacity while keeping doctors involved in decisions affecting each user.
Lončarević said the support reduced costs, shortened onboarding and helped the company deliver its service more efficiently.
The experience also strengthened Agesync’s commercial case. The company could show how its technology addressed a measurable operational constraint and how the service could support a growing number of users.
Developing an investment-ready business model
Agesync later joined the AI4Health.Cro Ready for Investment Program. The programme helped the team further develop its business model and prepare for investor discussions. This involved connecting the company’s technical progress with the practical questions investors ask how the service will grow, how clinical resources will be used and whether the model can remain sustainable as the customer base expands.
The hospital data and the resulting improvements in clinical workflow gave Agesync a stronger foundation for this work. The company could present evidence that its technology had reduced onboarding time and increased the number of users a doctor could support.
For a health tech company, these operational details shape the investment case. Investors need to understand how clinical oversight, technology and costs interact as a service grows.
Lončarević describes investor meetings as demanding and advises founders to present their companies honestly.
“You have to believe in your product, and that will be recognised,” he said.
He also emphasises persistence. A company may need to present its idea several times before reaching the right investor, particularly in healthcare, where founders must address questions spanning technology, medicine, regulation and finance.
Financing from AI4Health.Cro partner – Feelsgood Capital
Following its participation in the Ready for Investment Program, Agesync secured financing from Feelsgood Capital, an AI4Health.Cro consortium partner. The financing marked an important step in the company’s development. It followed a period in which Agesync had improved its technical workflow, strengthened the economics of its service and refined the way it presented its growth strategy.
The amount and terms of the financing have not been disclosed. Its wider significance lies in the sequence that led to it.
AI4Health.Cro first supported the company’s technical development through access to anonymised hospital data. The Ready for Investment Program then helped Agesync translate those improvements into a clearer business model. The connection with Feelsgood Capital provided a route to financing for the next stage of growth.
For Agesync, the value of the innovation ecosystem came from the way these forms of support worked together.
Preparing longevity care for growth
Lončarević expects interest in personalised preventive health to continue increasing. People are becoming more willing to share health information when it leads to clear and individual guidance, he says, while demand for longevity services is expanding from the United States into Europe.
Agesync will now need to continue developing a service that users trust, and clinicians can oversee efficiently. The platform must support sustained engagement across areas such as nutrition, exercise and sleep, while maintaining clear clinical responsibilities in more sensitive areas of care.
The company enters this stage with a more efficient workflow, an improved business model and new financing. Its experience shows how access to relevant health data, investment-readiness support and connections within the AI4Health.Cro ecosystem can help an early-stage health tech company move from product development towards financed growth.
Health tech companies preparing to raise capital can apply for support through the AI4Health.Cro Ready for Investment Program. The programme helps teams refine their business models, prepare for investor scrutiny and connect clinical and technical progress with a credible financing strategy.